# High Profile Transvalvular Pump Assisted Recovery for Takotsubo Cardiomyopathy: A Case Series

## TL;DR

This case series explores the use of high-profile transvalvular pumps to treat severe heart failure in patients with stress-induced cardiomyopathy, showing successful recovery.

## Contribution

Demonstrates the effectiveness of high-profile transvalvular pumps in managing cardiogenic shock due to stress-induced cardiomyopathy.

## Key findings

- Two patients with severe cardiogenic shock due to stress-induced cardiomyopathy showed significant hemodynamic improvement after HPTP implantation.
- Post-implantation echocardiograms showed normalization of left ventricular ejection fraction in both patients.
- HPTP facilitated surgical interventions and full cardiac recovery in complex clinical scenarios.

## Abstract

Background: Stress-induced cardiomyopathy (SI-CM) is a transient left ventricular dysfunction triggered by emotional or physical stress, often resolving with supportive care. However, severe cases may progress to cardiogenic shock (CS), requiring mechanical circulatory support (MCS). High-profile transvalvular pumps (HPTP), a form of percutaneous ventricular assist device, offer promising hemodynamic support in acute heart failure. This report explores HPTP use in SI-CM-related CS through two complex clinical cases. Case Summary: Two elderly female patients presented with severe CS secondary to apical-variant SI-CM. Case 1 involved a 67-year-old woman with sepsis, colonic perforation, and recurrent SI-CM, leading to profound low-output shock despite multiple vasopressors and inotropes. HPTP was implanted via the axillary artery, allowing for surgical management of intra-abdominal pathology and eventual cardiac recovery. Case 2 featured a 77-year-old woman with multifocal pneumonia, severe mitral regurgitation, and complete heart block. HPTP implantation stabilized her hemodynamics, facilitated extubation, and led to full recovery of ventricular function. Results: Both patients showed marked improvement in cardiac output and systemic perfusion following HPTP insertion. Echocardiograms post-device removal revealed normalization of left ventricular ejection fraction (55–64%). Hemodynamic data confirmed reduced pulmonary capillary wedge pressure and systemic vascular resistance. Conclusion: These cases highlight the potential of HPTP in managing SI-CM-related CS, especially when traditional therapies are inadequate or contraindicated. HPTP can rapidly restore hemodynamic stability and support myocardial recovery. While current data are limited, these observations underscore the need for broader investigation into the role of HPTP in this setting.